Table 3 Subgroup analysis of the prevalence of HBV and HCV in TGs based on male to female, female to male, and continents
Population | Subgroup | Number of studies | Pooled prevalence (95% CI) | Between studies | Between subgroups | ||||
|---|---|---|---|---|---|---|---|---|---|
I2 (%) | P heterogeneity | Q | Q | P heterogeneity | |||||
HCV in TGs | Type | MTF | 3 | 5% (1–9%) | 55.93 | 0.90 | 15.99 | 3.57 | 0.17 |
FTM | 1 | 8% (1–14%) | – | – | – | ||||
Both | 3 | 9% (2–15%) | 90.38 | 0.00 | 36.68 | ||||
Continent | Asia | 2 | 11% (3–19%) | 71.23 | 0.06 | 9.09 | 3.41 | 0.18 | |
America | 3 | 10% (5–25%) | 76.55 | 0.00 | 44.50 | ||||
Europe | 2 | 4% (1–6%) | 0.00 | 0.44 | 0.60 | ||||
HBV in TGs | Type | MTF | 3 | 6% (3–10%) | 79.54 | 0.07 | 10.90 | 1.14 | 0.56 |
FTM | 1 | 8% (1–14%) | – | – | – | ||||
Both | 3 | 18% (3–34%) | 88.90 | 0.00 | 17.68 | ||||
Continent | Asia | 1 | 9% (4–15%) | – | – | – | 8.27 | 0.04 | |
America | 3 | 16% (8–23%) | 76.55 | 0.00 | 44.8 | ||||
Europe | 2 | 5% (2–7%) | 0.00 | 0.44 | 0.37 | ||||
Africa | 1 | 10% (7–12%) | – | – | – | ||||